Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469.

Pharmacogenetics and genomics - 1 Feb 2014

Ramírez Jacqueline, Kim Tae Won, Liu Wanqing, Myers Jamie L, Mirkov Snezana, Owzar Kouros, Watson Dorothy, Mulkey Flora, Gamazon Eric R, Stock Wendy, Undevia Samir, Innocenti Federico, Ratain Mark J

Abstract excerpt

XK469 (NSC 697887) is a selective topoisomerase II β inhibitor eliminated mainly by aldehyde oxidase I (AOX1). We performed a candidate gene study to investigate whether AOX1 genetic variation contributes to interindividual variability in XK469 clearance. Forty-one AOX1 single nucleotide polymorphisms (SNPs) and seven liver expression quantitative trait loci were genotyped in White patients with advanced...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Clinical Trials, Phase I as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cohort Studies

Share to Neoplasms

Share to Pharmacogenetics

Share to Quantitative Trait Loci

Share to Quinoxalines

Source

Open in PubMed Open full text

Identifiers

PMID: 24300566
DOI: 10.1097/FPC.0000000000000023
PMCID: PMC3901533

Genes

AOX1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469.PMID 24300566Read ↗

The role of aldehyde oxidase in drug metabolism.Semantic proximity Read ↗

In Vitro Evaluation of the Reductase Activities of Human AKR1C3 Allelic Variants.Semantic proximity Read ↗

Functional characterization of human xanthine oxidase allelic variants.Semantic proximity Read ↗

Optimization of the Expression of Human Aldehyde Oxidase for Investigations of Single-Nucleotide Polymorphisms.Semantic proximity Read ↗

Structural basis for the role of mammalian aldehyde oxidases in the metabolism of drugs and xenobiotics.Semantic proximity Read ↗

Investigating the Role of Missense SNPs on ALDH 1A1 mediated pharmacokinetic resistance to cyclophosphamide.Semantic proximity Read ↗

Genetic variants of aldehyde oxidase (AOX) 1 in cynomolgus and rhesus macaques.Semantic proximity Read ↗

Genomic sequencing of uric acid metabolizing and clearing genes in relationship to xanthine oxidase inhibitor dose.Semantic proximity Read ↗

Evaluation of Icotinib as a Potent and Selective Inhibitor of Aldehyde Oxidase for Reaction Phenotyping in Human Hepatocytes.Semantic proximity Read ↗

Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin.Semantic proximity Read ↗

A single nucleotide polymorphism causes enhanced radical oxygen species production by human aldehyde oxidase.Semantic proximity Read ↗

Impact of nonsynonymous single nucleotide polymorphisms on in-vitro metabolism of exemestane by hepatic cytosolic reductases.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.